Cogent Biosciences (COGT) Competitors $6.48 -0.13 (-1.97%) Closing price 04:00 PM EasternExtended Trading$6.48 +0.00 (+0.08%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. VKTX, RYTM, SRRK, CRNX, MRUS, PTGX, APLS, BHVN, MTSR, and ACADShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Biohaven (BHVN), Metsera (MTSR), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Viking Therapeutics Rhythm Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Merus Protagonist Therapeutics Apellis Pharmaceuticals Biohaven Metsera ACADIA Pharmaceuticals Viking Therapeutics (NASDAQ:VKTX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership. Is VKTX or COGT more profitable? Viking Therapeutics' return on equity of -11.93% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -11.93% -11.57% Cogent Biosciences N/A -112.55%-60.44% Does the MarketBeat Community prefer VKTX or COGT? Viking Therapeutics received 339 more outperform votes than Cogent Biosciences when rated by MarketBeat users. Likewise, 80.03% of users gave Viking Therapeutics an outperform vote while only 70.22% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformViking TherapeuticsOutperform Votes62980.03% Underperform Votes15719.97%Cogent BiosciencesOutperform Votes29070.22% Underperform Votes12329.78% Do institutionals & insiders have more ownership in VKTX or COGT? 76.0% of Viking Therapeutics shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by company insiders. Comparatively, 5.9% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, VKTX or COGT? Viking Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Do analysts rate VKTX or COGT? Viking Therapeutics presently has a consensus price target of $95.18, suggesting a potential upside of 264.26%. Cogent Biosciences has a consensus price target of $14.43, suggesting a potential upside of 118.28%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has higher earnings and valuation, VKTX or COGT? Viking Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.00-26.13Cogent BiosciencesN/AN/A-$192.41M-$1.94-3.41 Does the media refer more to VKTX or COGT? In the previous week, Viking Therapeutics had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 20 mentions for Viking Therapeutics and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.05 beat Viking Therapeutics' score of 0.85 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryViking Therapeutics beats Cogent Biosciences on 11 of the 15 factors compared between the two stocks. Remove Ads Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$752.55M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-2.677.2023.1419.03Price / SalesN/A226.01385.7893.17Price / CashN/A65.6738.1634.64Price / Book2.876.476.934.33Net Income-$192.41M$141.90M$3.20B$247.06M7 Day Performance-7.68%-3.20%-2.30%-0.37%1 Month Performance-12.22%-5.64%2.86%-3.85%1 Year Performance-1.64%-7.47%10.66%1.27% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.3849 of 5 stars$6.48-2.0%$14.43+122.7%+1.4%$737.75MN/A-2.6180Positive NewsVKTXViking Therapeutics4.3106 of 5 stars$29.83-3.4%$97.67+227.4%-68.6%$3.35BN/A-29.8320Analyst ForecastRYTMRhythm Pharmaceuticals4.4103 of 5 stars$52.34+2.7%$69.31+32.4%+28.0%$3.31B$130.13M-12.09140Analyst RevisionSRRKScholar Rock3.9969 of 5 stars$34.72+0.3%$40.43+16.4%+115.9%$3.29B$33.19M-14.77140Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals4.3203 of 5 stars$35.20+2.1%$72.64+106.4%-21.4%$3.28B$1.04M-9.44210Analyst ForecastMRUSMerus2.3624 of 5 stars$47.22+0.3%$85.31+80.7%+0.2%$3.26B$36.13M-11.9537Analyst ForecastPTGXProtagonist Therapeutics3.6882 of 5 stars$53.01-3.2%$61.22+15.5%+73.6%$3.25B$434.43M19.93120Analyst ForecastPositive NewsAPLSApellis Pharmaceuticals4.3456 of 5 stars$25.11+1.8%$45.53+81.3%-58.5%$3.15B$781.37M-12.37770Positive NewsBHVNBiohaven3.8958 of 5 stars$29.73+2.0%$63.15+112.4%-50.3%$3.03BN/A-3.18239MTSRMetseraN/A$28.38+12.6%$47.00+65.6%N/A$2.92BN/A0.0081Earnings ReportNews CoverageACADACADIA Pharmaceuticals4.1366 of 5 stars$17.20-1.7%$24.00+39.5%-5.5%$2.87B$957.80M22.05510 Remove Ads Related Companies and Tools Related Companies Viking Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Scholar Rock Alternatives Crinetics Pharmaceuticals Alternatives Merus Alternatives Protagonist Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Biohaven Alternatives Metsera Alternatives ACADIA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
